Bayer AG BAYN

Bayer has delivered a sharp share price recovery over the past year, which puts fresh attention on a simple question about the stock: Are investors now paying a price that still lines up with what the business generates in sales? Bayer’s 83.8% 1 year return puts a lot of recent optimism on trial against what the company’s revenue base can realistically support. New U.S. regulatory milestones for therapies like Lynkuet for vasomotor symptoms in breast cancer patients and KERENDIA for chronic...

AI, machine learning, cloud analytics and multi-omics are accelerating drug discovery, enabling targeted, personalized therapies while reducing development time, cost and risk.Dublin, Sept. 29, 2026 (GLOBE NEWSWIRE) -- "Computer-Aided Drug Discovery - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global computer-aided drug discovery market was estimated at US$3.2 billion in 2025 and is projected to reach US$6.7 billion by 2032, expanding at a compound

SAN DIEGO, September 29, 2026--Vividion announces publication of first peer-reviewed clinical data from Phase 1 study of VVD-214, investigational oral inhibitor of WRN.

Bayer (XTRA:BAYN) said the U.S. FDA has accepted a supplemental New Drug Application for Lynkuet (elinzanetant) for review. The filing covers moderate to severe vasomotor symptoms in women receiving endocrine therapy for hormone receptor-positive breast cancer. The FDA granted priority review status, indicating an accelerated assessment timeline compared with a standard review process. The priority review for Lynkuet in endocrine therapy related vasomotor symptoms is only one part of the...

WHIPPANY, N.J., September 29, 2026--Bayer today announced the launch of MiraSOFT, a new stool softener option from the makers of MiraLAX® with the active ingredient docusate sodium designed to help gently soften hard, dry stools and support more comfortable, easier bowel movements. * MiraSOFT is now available at over 7,000 CVS Pharmacy locations and at cvs.com.

If approved, Zenkuda will compete with blockbuster wAMD sellers like Eylea and Vabysmo.

WHIPPANY, N.J., September 28, 2026--Today Bayer announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental New Drug Application (sNDA) and granted Priority Review designation for Lynkuet® (elinzanetant) under investigation for the treatment of moderate to severe vasomotor symptoms (VMS, also known as hot flashes) in women receiving endocrine therapy for treatment of breast cancer. First approved by the FDA in October 2025 for the treatment of moderate to s

Elanco Animal Health (NYSE:ELAN) President and CEO Jeff Simmons outlined the company’s growth strategy, product launches, deleveraging plans and outlook for its pet health and farm animal businesses during the Bank of America Healthcare Conference in London. Simmons said Elanco delivered 10% report

RXRX's strategic partnerships are expanding its drug pipeline, strengthening AI capabilities and providing non-dilutive funding through early 2028.

Treatment of chronic kidney disease (CKD) focuses on slowing disease progression toward kidney failure, reducing cardiovascular risk, and addressing complications such as anemia and mineral bone disorders. SGLT2 inhibitors, non-steroidal mineralocorticoid receptor antagonists (MRAs), and emerging aldosterone synthase inhibitor combinations are increasingly replacing single-agent RAS blockade, driven by their improved renal and cardiovascular outcomes. Approved therapies in the CKD market include

Last week at Odyssey, its flagship gathering of the leaders who run global supply chains, GoComet launched Nova, an AI-native execution layer for enterprise logistics. The Singapore edition was attended by over 150 supply chain and logistics leaders from global enterprises, including Shell, BHP, Bayer, L'Oréal and DP World.

Grünenthal, a global leader in pain management and research, today announced an agreement with Bayer AG to acquire Stivarga®, an oral treatment for specific advanced cancers, for up to €375 million. The acquisition is subject to customary closing conditions, including approval by the relevant regulatory authorities. The acquisition is expected to close by the end of 2026 or early 2027.

Bayer's Kerendia gains FDA approval for CKD linked to type 1 diabetes, expanding its patient reach and growth prospects.

CAMBRIDGE, Mass., September 17, 2026--Robigo, a biotechnology company engineering no-compromise biological solutions for crop protection, today announced a Series A funding led by Leaps by Bayer with participation from Illumina Ventures, SVG Thrive, Congruent Ventures, and Endeavor8. The round will accelerate the commercial launch of engineered microbial biopesticides combatting fungal diseases in soybeans and specialty crops in the United States, making these biologicals economically viable wit

WHIPPANY, N.J., September 17, 2026--Bayer Summary Bayer today announced that the U.S. Food and Drug Administration (FDA) approved KERENDIA® (finerenone) to reduce urinary albumin-to-creatinine ratio (UACR), which is expected to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline and end-stage kidney disease in adults with chronic kidney disease (CKD) associated with type 1 diabetes (T1D), following the agency’s Priority Review of the supplemental New Drug Application

Bayer (XTRA:BAYN) just received accelerated FDA approval for sevabertinib as a first-line therapy for certain HER2-mutant lung cancer patients, which puts a fresh spotlight on how its pharmaceutical pipeline might influence investor sentiment. Against that backdrop, Bayer shares have climbed strongly this year. The 90 day share price return is 31.84% and the year to date share price return is 28.89%, while the 1 year total shareholder return of 79.40% suggests recent momentum has followed a...

KKR joins Apollo as a minority participantNEW YORK and LEVERKUSEN, Germany, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Apollo (NYSE: APO) today announced that Apollo-managed funds and affiliates (“Apollo”) have successfully closed a €3 billion capital solution for Bayer, previously announced on July 10. KKR has joined Apollo as a significant minority participant in the investment. Under the transaction, Apollo, together with KKR, have invested equity capital into a newly established entity holding Bayer